Valuation : OraSure Technologies, Inc.

Market Cap 234M 201M 189M 173M 322M 22.17B 324M 2.24B 867M 11.33B 878M 859M 36.05B P/E 2026 *
-5.14x
P/E 2027 * -4.19x
Enterprise Value 234M 201M 189M 173M 322M 22.17B 324M 2.24B 867M 11.33B 878M 859M 36.05B EV / Sales 2026 *
1.91x
EV / Sales 2027 * 1.76x
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-7.20%
Current month-6.69%
1 month-16.25%
3 months-20.99%
6 months+4.69%
Current year+38.43%
1 week 3.33
Extreme 3.33
3.65
1 month 3.33
Extreme 3.33
4.1
Current year 2.33
Extreme 2.33
4.58
1 year 2.08
Extreme 2.08
4.58
3 years 2.08
Extreme 2.08
8.45
5 years 2.08
Extreme 2.08
13.57
10 years 2.08
Extreme 2.08
23.01
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-03
Director of Finance/CFO 54 2022-08-07
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Director/Board Member 59 2020-05-31
Director/Board Member 66 2021-11-07
Director/Board Member 52 2022-06-03
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Free

Director

46,106 0.0670%
6/3/26 Free

Director

46,106 0.0670%
6/3/26 Free

Director

46,106 0.0670%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-7.20%0.00%-44.35% 234M
+0.74%-4.35%-19.92%+3.14% 183B
+0.90%+0.35%-1.67%+13.64% 118B
-0.61%-3.60%+8.56%+82.43% 61.96B
-0.49%-4.95%+12.81%+44.34% 50.6B
+1.47%-4.84%-6.32%-33.21% 48.78B
-1.30%-7.05%+6.34%-22.29% 31.9B
-1.44%-5.52% - - 30.44B
+0.41%-1.79%+33.50%-15.28% 23.77B
-2.51%-8.14%-13.24%+5.88% 22.26B
Average -0.36%-2.85%+2.23%+3.81% 57.07B
Weighted average by Cap. +0.18%-1.89%-4.18%+12.89%

Financials

2026 *2027 *
Net sales 122M 105M 98.77M 90.14M 168M 11.58B 169M 1.17B 453M 5.92B 459M 449M 18.83B 133M 115M 108M 98.33M 183M 12.63B 184M 1.28B 494M 6.45B 500M 489M 20.54B
Net income -46.2M -39.72M -37.37M -34.1M -63.64M -4.38B -63.97M -443M -171M -2.24B -173M -170M -7.12B -57.65M -49.57M -46.64M -42.56M -79.42M -5.47B -79.83M -553M -214M -2.79B -216M -212M -8.89B
Net Debt - -
Logo OraSure Technologies, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Employees
500
Date Price Change Volume
26-09-09 $3.350 -1.18% 28,337
26-09-08 $3.390 -2.59% 354,251
26-09-04 $3.480 -2.79% 304,665
26-09-03 $3.580 -0.83% 211,264
26-09-02 $3.610 +2.27% 345,282
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.390USD
Average target price
4.000USD
Spread / Average Target
+17.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OSUR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!